Join to View Full Profile
979 E 3rd StSte C830Chattanooga, TN 37403
Phone+1 423-778-9001
Fax+1 423-778-4692
Dr. Shah is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Duke University HospitalFellowship, Vascular Neurology, 2014 - 2015
Cooper Medical School of Rowan University/Cooper University HospitalResidency, Neurology, 2012 - 2015
Grand Rapids Medical Education and Research Center/ Michigan State University (St Mary's)Internship, Transitional Year, 2011 - 2012
M.P. Shah Medical CollegeClass of 2010
Certifications & Licensure
FL State Medical License 2019 - 2026
GA State Medical License 2019 - 2026
IL State Medical License 2019 - 2026
WA State Medical License 2024 - 2026
KY State Medical License 2021 - 2026
VT State Medical License 2023 - 2026
VA State Medical License 2021 - 2026
American Board of Psychiatry and Neurology Neurology- American Board of Psychiatry and Neurology Vascular Neurology
- Join now to see all
Publications & Presentations
PubMed
- Factors Influencing Nerinetide Effect on Infarct Volume in Patients Without Alteplase in the Randomized ESCAPE-NA1 Trial.Johanna M Ospel, Mayank Goyal, Bijoy K Menon, Mohammed A Almekhlafi, Charlotte Zerna
Stroke. 2025-01-01 - Factors Influencing Nerinetide Effect on Clinical Outcome in Patients Without Alteplase Treatment in the ESCAPE-NA1 Trial.Mayank Goyal, Bijoy K Menon, Johanna Ospel, Mohammed Almekhlafi, Charlotte Zerna
Journal of Stroke. 2025-01-01 - Enhancing the diagnostic efficacy of right-to-left shunt using robot-assisted transcranial Doppler: a quality improvement project.Ruchir Shah, Christian Devlin, Lan Gao, Samuel Ledford, Vimal Ramjee
Frontiers in Neurology. 2025-01-01
Press Mentions
Acticor Biotech Announces the Enrollment of the First US Patient in Its Phase 2/3 Study ACTISAVE for the Treatment of StrokeSeptember 26th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
